

CLAIM AMENDMENTS

1. (Currently Amended) A composition comprising an interleukin-2 receptor associated polypeptide, wherein said interleukin-2 receptor associated ~~polypeptide~~ polypeptide is reactive with the monoclonal antibody produced by the hybridoma PTA-82, and said interleukin-2 receptor associated polypeptide has a molecular weight of about 32,000 to 34,000 daltons as determined by SDS-PAGE.

2. (Canceled)

3. (Currently Amended) A composition comprising ~~the an~~ an interleukin-2 receptor associated polypeptide ~~of Claim 1~~, wherein said interleukin-2 receptor associated polypeptide is reactive with the monoclonal antibody produced by the hybridoma PTA-82, and said interleukin-2 receptor associated polypeptide has a molecular weight of about 26,000 to 28,000 daltons as determined by SDS-PAGE.

4. (Original) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 1, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and HuT 102 cells.

5. (Original) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 1, wherein said interleukin-2 associated polypeptide associates with the interleukin-2 Ra subunit.

Claims 6.-8. (Canceled)

9. (Currently Amended) A method for purifying an interleukin-2 receptor associated polypeptide, wherein said method comprises contacting cells expressing interleukin-2 receptors and interleukin-2 receptor associated polypeptide ~~protein~~, with an anti-interleukin-2 receptor associated polypeptide antibody under conditions wherein said antibody forms a complex with said interleukin-2 receptor associated polypeptide expressed by said cells.

10. (Original) The method of Claim 9, wherein said cells expressing said interleukin-2 receptor and interleukin-2 receptor associated protein are solubilized prior to said contacting of said cells with said antibody.

11. (Original) The method of Claim 10, wherein said anti-interleukin-2 receptor associated polypeptide antibody is present on an immunoaffinity column.

12. (Currently Amended) The method of Claim 11, wherein said interleukin-2 receptor associated protein bound to said anti-interleukin-2 receptor associated polypeptide ~~ILRAP~~ antibody is eluted from said column.

13. (Currently Amended) The method of Claim 9, wherein said cells expressing interleukin-2 receptor and said interleukin-2 receptor associated polypeptide are selected from the group consisting of cells lines expressing interleukin-2R α and cell lines expressing interleukin-2R β subunits.

14. (Original) The interleukin-2 receptor associated polypeptide of Claim 13, wherein said interleukin-2 receptor expressing cells are Kit 225 cells.

15. (Original) A composition comprising an interleukin-2 receptor associated polypeptide purified by the method of Claim 9.

Claims 16:-21.(Canceled)

22. (New) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 3, wherein said interleukin-2 receptor associated polypeptide is expressed by cells selected from the group consisting of Kit-225 cells and HuT 102 cells.

23. (New) A composition comprising the interleukin-2 receptor associated polypeptide of Claim 3, wherein said interleukin-2 associated polypeptide associates with the interleukin-2 R α subunit.